

Ublituximab-xiiy (Briumvi) Patient Referral Form

Admissions Fax # 844-878-6917

Admissions Phone # 855-WE-R-RARE (855-937-7273)

Patient Demographics Information										
Patient Name						SSN#		DOB		
Patient Address						I				
Primary Phone				Cellular Phone			Work Phone			
Emergency Contact Name, Relationship				I			Emergency Contact Phone Number			
Additional D	ocumentation I	Needed								
Copy of insurant	ce cards			y and Physical			t vitals including bloc		e	
	et w/demographics		& CBC w	/dif, BMP, & CMP		✤ Screen	ing for HBV infection	1		
	ance Informati	on			Insurance Plan #2					
Insurance Plan #1				Insurance Plan #2						
Subscriber Name			DOB		Subscriber Name			DOB		
Policy Number Group					Policy Number Group ID					
Patient Clinical Information										
Gender	Height (inches)	Weight (lbs)	Allergies	(food/drug)						
	<i>S</i> (<i>,</i>	5 ()	Ŭ	(, , ,						
Statement of Medical Necessity / Primary Diagnosis										
ICD10: Description of diagnosis:										
	nformation / P			'S						
Medication		Directi					*If subsequent treatment cycles only			
	Briumvi		<pre>per manufacturer guidelines OR over hours. rate according to package insert.</pre>							
	DHUIIIVI	litration	rate accor	ding to package inse	ert.		Date of last infusior	1:		
□ First Infusion										
150 mg IV day 1, #1 dose, no refill										
□ Second Infusion (2 weeks later) and Subsequent Infusions Next dose due:										
	450 mg IV 2 weeks following first infusion and then every 24 weeks thereafter, #2 doses, refill x12 months OR									
Line Access								Ouanti	ity/Refills	
RN to start peripheral IV or use existing CVAD. RN to administer catheter flushing and medications per Heritage Biologics policy.									Dispense: Quantity #QS + PRN refills unless otherwise noted	
·····										
□ Sodium Chloride 0.9% 10 mL STERILE Flush: Flush with 5-10 mL STERILE sodium chloride 0.9% IV as needed for port access. □ Other □ Heparin Lock 100U/mL 5 mL Flush: Lock with 5 mL heparin 100U/mL after each use or daily while port is accessed.										
Premedications										
Give premedication 30 minutes prior to infusion (generics will be dispensed)										
Diphenhydramine: 25-50 mg PO										
Methylprednisolone: 125 mg slow IV push over 5 minutes										
Acetaminophen:										
EMLA topical cream (Lidocaine 2.5% and Prilocaine 2.5%): apply to IV site prior to access PRN for pain upon needle insertion.										
□ Sodium Chloride 0.9% 500 mL - 1000 mL IV over 1-2 hours as tolerated daily PRN for hydration and/or headache. □ Other (Physician to specify):										
Adverse Read	tion Orders									
In the event of an infusion reaction (ie: fever, chills, backache, headache, rigors) the following orders will be followed and physician will be notified.										
Mild reaction: Pause infusion for 10 minutes, resume infusion at a minumum 50% reduction in rate after symptoms have resolved.										
Moderate reaction: Pause infusion, administer diphenhydramine 25 mg IV; administer sodium chloride 0.9% 500mL IV bolus. If symptoms persist,										
administer remaining diphenhydramine 25 mg IV. Administer diphenhydramine IM if no IV access. Notify Pharmacist.										
	chloride 0.9% 500 m					Jung IV	x 1 003e,			
Prescriber Information										
Physician Name					Office Contact					
Practice Address					Practice Phone					
NPI# License #						DEA#				
				-					-	
Physician Signatur	e Required - Substitu	tion Permitted		Date	Physician Signature Required	- Dispense	e as Written		Date	
									1	